SUBSCRIBE
SUBSCRIBE
News   Drug Development

BerGenBio AS Initiates Preclinical Development of Novel AXL Inhibitor BGB324

October 31, 2011 | 
1 min read
BERGEN, Norway--(BUSINESS WIRE)--BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
Preclinical Europe
MORE ON THIS TOPIC
Brain shaped maze. Conceptual image of science and medicine. 3D illustration.
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
 · 
3 min read
 · 
Annalee Armstrong
A vibrant geometric pattern of colorful book spines arranged neatly on shelves. This texture represents organized knowledge and information storage. The minimalist composition and bright colors are ideal for educational, corporate, or creative graphic design projects.
Insights
GPCRs, radiopharma and the rise of functional peptide screening
May 14, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Lightbulb with tangled lines. Problem solving and brainstorming Idea concept. Vector illustration
Gene therapy
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
May 14, 2026
 · 
3 min read
 · 
Annalee Armstrong
Solution and strategy path questions and clear planning for ideas in business leadership with a straight path to success choosing the right strategic plan with yellow traffic signs cutting through a maze of highways.
Alzheimer’s disease
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
May 14, 2026
 · 
3 min read
 · 
Tristan Manalac